Sign In
Buy ATAI
$4.53
-0.280 (-5.82%)
At Close: Jun 03, 2026
AtaiBeckley advances clinical pipeline, strengthens balance sheet in Q3
08:41am, Wednesday, 12'th Nov 2025
AtaiBeckley NV (NASDAQ:ATAI, ETR:9VC) reported continued clinical and operational progress during the third quarter of 2025, advancing multiple programs targeting treatment-resistant depression (TRD)
Oklo highlights operational milestones, progress towards Aurora commercialization in Q3
11:21am, Tuesday, 11'th Nov 2025
Oklo (NYSE:OKLO) continued to invest in its pre-commercial nuclear technology during Q3, achieving several operational and regulatory milestones. Oklo...
Atai Beckley N.V. (ATAI) Discusses BPL-003 Phase IIb Open-Label Extension Study Results in Treatment Resistant Depression Transcript
09:21am, Tuesday, 11'th Nov 2025
Atai Beckley N.V. ( ATAI ) Discusses BPL-003 Phase IIb Open-Label Extension Study Results in Treatment Resistant Depression November 10, 2025 8:00 AM EST Company Participants Ashleigh Barreto Srinivas
AtaiBeckley reports positive data supporting repeated dosing of BPL-003 in treatment-resistant depression patients
09:15am, Monday, 10'th Nov 2025
AtaiBeckley NV (NASDAQ:ATAI, ETR:9VC) has unveiled positive topline results from the open-label extension (OLE) study of its Phase 2b clinical trial evaluating BPL-003 in patients with treatment-resis
atai Life Sciences and Beckley Psytech complete strategic combination to form AtaiBeckley
08:45am, Wednesday, 05'th Nov 2025
atai Life Sciences (NASDAQ:ATAI, ETR:9VC) announced that its previously annoucned strategic combination with Beckley Psytech has been completed, forming a new clinical-stage biopharmaceutical company
atai Life Sciences closes $149.5M public offering, extending cash runway into 2029
08:59am, Tuesday, 21'st Oct 2025
atai Life Sciences (NASDAQ:ATAI, ETR:9VC) announced the completion of a $149.5 million public offering of approximately 27 million common shares, including the full exercise of underwriters' option to
atai Life Sciences Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Common Shares
05:29pm, Monday, 20'th Oct 2025
Cash, cash equivalents, short-term investments and other liquid assets expected to fund operations into 2029, beyond anticipated top-line results from the first Phase 3 clinical trial of BPL-003 Cash,
atai Life Sciences (ATAI) Upgraded to Buy: Here's Why
01:00pm, Monday, 20'th Oct 2025
atai Life Sciences (ATAI) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Atai Life Sciences And Beckley Psytech: Promising Emerging Leader In Psychedelics
09:00am, Monday, 20'th Oct 2025
ATAI's main value driver is BPL-003. This candidate showed rapid and durable TRD benefits in its Phase 2b trials. BPL-003's 8 mg dose seemed to be ideal, which is why ATAI is going ahead with a Phase
atai Life Sciences to raise $130M in public stock offering
08:23am, Friday, 17'th Oct 2025
atai Life Sciences (NASDAQ:ATAI, ETR:9VC) announced that it has priced its registered underwritten offering of 23,725,000 company common shares at $5.48 per share, with expectations of raising
Why Atai Life Sciences Stock Was So Lively This Week
08:06am, Friday, 17'th Oct 2025
Atai Life Sciences (ATAI -7.63%), a biotech focused on developing psychedelic-based medicines to treat mental health disorders, was a standout stock over the past few days in its rather limited peer g
atai Life Sciences Announces Pricing of Public Offering of Common Shares
10:31pm, Thursday, 16'th Oct 2025
NEW YORK and AMSTERDAM, Oct. 16, 2025 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical company focused on transforming the treat
atai Life Sciences and Beckley Psytech secure FDA Breakthrough Therapy Designation for BPL-003 in treatment-resistant depression
04:53pm, Thursday, 16'th Oct 2025
atai Life Sciences (NASDAQ:ATAI, ETR:9VC) and Beckley Psytech announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to BPL-003 (mebufotenin benzoate) na
atai Life Sciences Announces Proposed Public Offering of Common Shares
04:12pm, Thursday, 16'th Oct 2025
NEW YORK and AMSTERDAM, Oct. 16, 2025 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical company focused on transforming the treatm
NEW YORK and AMSTERDAM, Oct. 16, 2025 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai” or “Company”), and Beckley Psytech Limited (“Beckley Psytech”), who previously announced
